21 research outputs found

    ΠžΡ€Π³Π°Π½ΠΎΠΏΡ€ΠΎΡ‚Π΅ΠΊΡ†ΠΈΡ ΠΈ ΠΏΡ€Π΅Π΄ΡƒΠΏΡ€Π΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ ΠΏΠΎΠ»ΠΈΠΎΡ€Π³Π°Π½Π½ΠΎΠΉ нСдостаточности ΠΏΡ€ΠΈ чрСскоТном ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½ΠΎΠΌ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π΅ высокого риска Π² условиях ΡΠΊΡΡ‚Ρ€Π°ΠΊΠΎΡ€ΠΏΠΎΡ€Π°Π»ΡŒΠ½ΠΎΠΉ ΠΌΠ΅ΠΌΠ±Ρ€Π°Π½Π½ΠΎΠΉ оксигСнации

    Get PDF
    Aim. To compare the possibilities of venoarterial extracorporeal membrane oxygenation (VA ECMO) and intra-aortic balloon pump (IABP) to prevent organ damage and the development of multiple organ failure.Methods. According to the inclusion and exclusion criteria, 51 patients underwent the study. The patients were divided into 2 groups depending on the method of mechanical circulatory support used: VA ECMO (n = 29) and IABP (n = 22). To assess organ functions in the intra- and postoperative period, the results of instrumental and laboratory research methods, as well as data from complex scales of organ dysfunction, were analased.Results. Myocardial depression was observed in the IABP group in the intraoperative period of high-risk percutaneous coronary intervention and worse hemodynamic stability compared to the VA ECMO group was traced. Organ dysfunction and multiorgan failure developed more often in the IABP group, which was confirmed by laboratory specific markers.Conclusion. High-risk percutaneous coronary intervention with VA ECMO is accompanied by a lower incidence and severity of organ damage and multiple organ failure. Thus, the VA ECMO has better organ protective effects. ЦСль. Π‘Ρ€Π°Π²Π½ΠΈΡ‚ΡŒ возмоТности Π²Π΅Π½ΠΎΠ°Ρ€Ρ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΡΠΊΡΡ‚Ρ€Π°ΠΊΠΎΡ€ΠΏΠΎΡ€Π°Π»ΡŒΠ½ΠΎΠΉ ΠΌΠ΅ΠΌΠ±Ρ€Π°Π½Π½ΠΎΠΉ оксигСнации (ВА ЭКМО) ΠΈ Π²Π½ΡƒΡ‚Ρ€ΠΈΠ°ΠΎΡ€Ρ‚Π°Π»ΡŒΠ½ΠΎΠΉ Π±Π°Π»Π»ΠΎΠ½Π½ΠΎΠΉ ΠΊΠΎΠ½Ρ‚Ρ€ΠΏΡƒΠ»ΡŒΡΠ°Ρ†ΠΈΠΈ (Π’ΠΠ‘Πš) ΠΏΡ€Π΅Π΄ΡƒΠΏΡ€Π΅ΠΆΠ΄Π°Ρ‚ΡŒ ΠΎΡ€Π³Π°Π½Π½ΠΎΠ΅ ΠΏΠΎΠ²Ρ€Π΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ ΠΈ Ρ€Π°Π·Π²ΠΈΡ‚ΠΈΠ΅ ΠΏΠΎΠ»ΠΈΠΎΡ€Π³Π°Π½Π½ΠΎΠΉ нСдостаточности.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Богласно критСриям Π²ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΡ ΠΈ ΠΈΡΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΡ, Π² исслСдованиС вошСл 51 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚. Π’ зависимости ΠΎΡ‚ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΡƒΠ΅ΠΌΠΎΠ³ΠΎ ΠΌΠ΅Ρ‚ΠΎΠ΄Π° мСханичСской ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΊΠΈ кровообращСния Π±ΠΎΠ»ΡŒΠ½Ρ‹Π΅ Ρ€Π°Π·Π΄Π΅Π»Π΅Π½Ρ‹ Π½Π° Π΄Π²Π΅ Π³Ρ€ΡƒΠΏΠΏΡ‹: ВА ЭКМО (n = 29) ΠΈ Π’ΠΠ‘Πš (n = 22). Π‘ Ρ†Π΅Π»ΡŒΡŽ ΠΎΡ†Π΅Π½ΠΊΠΈ ΠΎΡ€Π³Π°Π½Π½Ρ‹Ρ… Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΉ Π² ΠΈΠ½Ρ‚Ρ€Π°- ΠΈ послСопСрационном ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π΅ ΠΏΡ€ΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½Ρ‹ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ ΠΈΠ½ΡΡ‚Ρ€ΡƒΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½Ρ‹Ρ… ΠΈ Π»Π°Π±ΠΎΡ€Π°Ρ‚ΠΎΡ€Π½Ρ‹Ρ… ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠ² исслСдования, Π° Ρ‚Π°ΠΊΠΆΠ΅ Π΄Π°Π½Π½Ρ‹Π΅ комплСксных шкал ΠΎΡ€Π³Π°Π½Π½ΠΎΠΉ дисфункции.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Π’ ΠΈΠ½Ρ‚Ρ€Π°ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΎΠ½Π½ΠΎΠΌ ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π΅ чрСскоТного ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½ΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π° высокого риска Π² Π³Ρ€ΡƒΠΏΠΏΠ΅ Π’ΠΠ‘Πš ΠΎΡ‚ΠΌΠ΅Ρ‡Π΅Π½Ρ‹ дСпрСссия ΠΌΠΈΠΎΠΊΠ°Ρ€Π΄Π° ΠΈ Ρ…ΡƒΠ΄ΡˆΠ°Ρ, Π² сравнСнии с ВА ЭКМО, гСмодинамичСская ΡΡ‚Π°Π±ΠΈΠ»ΡŒΠ½ΠΎΡΡ‚ΡŒ. ΠžΡ€Π³Π°Π½Π½Π°Ρ дисфункция ΠΈ полиорганная Π½Π΅Π΄ΠΎΡΡ‚Π°Ρ‚ΠΎΡ‡Π½ΠΎΡΡ‚ΡŒ Ρ‡Π°Ρ‰Π΅ Ρ€Π°Π·Π²ΠΈΠ²Π°Π»ΠΈΡΡŒ Π² Π³Ρ€ΡƒΠΏΠΏΠ΅ Π’ΠΠ‘Πš, Ρ‡Ρ‚ΠΎ ΠΏΠΎΠ΄Ρ‚Π²Π΅Ρ€ΠΆΠ΄Π΅Π½ΠΎ Π»Π°Π±ΠΎΡ€Π°Ρ‚ΠΎΡ€Π½Ρ‹ΠΌΠΈ спСцифичСскими ΠΌΠ°Ρ€ΠΊΠ΅Ρ€Π°ΠΌΠΈ.Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. ЧрСскоТноС ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½ΠΎΠ΅ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΠΎ высокого риска Π² условиях ВА ЭКМО сопровоТдаСтся мСньшими частотой развития ΠΈ Π²Ρ‹Ρ€Π°ΠΆΠ΅Π½Π½ΠΎΡΡ‚ΡŒΡŽ ΠΎΡ€Π³Π°Π½Π½ΠΎΠ³ΠΎ поврСТдСния ΠΈ ΠΏΠΎΠ»ΠΈΠΎΡ€Π³Π°Π½Π½ΠΎΠΉ нСдостаточности. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±Ρ€Π°Π·ΠΎΠΌ, ВА ЭКМО ΠΎΠΊΠ°Π·Ρ‹Π²Π°Π΅Ρ‚ Π»ΡƒΡ‡ΡˆΠ΅Π΅ ΠΎΡ€Π³Π°Π½ΠΎΠΏΡ€ΠΎΡ‚Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΠ΅ дСйствиС.

    IMMUNOSUPPRESSION AS A COMPONENT OF MULTIPLE ORGAN DYSFUNCTION SYNDROME FOLLOWING CARDIAC SURGERY

    Get PDF
    Aim. To defne the role of myeloid-derived suppressor cells in the development of persistent multiple organ dysfunction followed cardiac surgeries with cardiopulmonary bypass.Methods. 40 patients who have undergone cardiac surgery were included in the study. Granulocyte myeloid-derived suppressor cells (G-MDSC) were defned as cells with the HLA-DR– / CD11Ξ²+ / CD15+ / CD33+ phenotype, and monocytic MDSC (M-MDSC) as cells with the HLA-DR– / CD11Ξ²+ / CD14+ / CD33+ phenotype using flow cytometry. Levels of cytokines, IL-1Ξ², IL-6, TNF-Ξ±, and IL-10 were measured with an enzyme immunoassay. All patients were assigned to three groups: Group 1 – patients with the uncomplicated postoperative period (n = 14), Group 2 – patients with non-persistent MODS and its early resolution (n = 16), and Group 3 – patients with persistent MODS at day 7.Results. We observed an increase in M-MDSCs and G-MDSC at day 1 following cardiac surgery. The most pronounced increase was found in monocytic-myeloid derived suppressor cells, i.e. an 8-fold increase in M-MDSCs in all study groups at day 1 after surgery. The number of M-MDSCs remained high in patients with persistent MODS at day 7 after cardiac surgery. Levels of IL-6 and IL-10 increased at day 1 after surgery. IL-6 reached its peak level, signifcantly exceeding baseline levels. By day 7, blood levels of all cytokines have decreased, except IL-10 levels, which remained above the baseline in patients with persistent MODS.Conclusion. An increase in M-MDSCs and elevated serum levels of the anti-inflammatory cytokine IL-10 have been found in patients regardless of the presence or absence of the complications in the early postoperative period after cardiac surgery with cardiopulmonary bypass. Persistent MODS with the SOFA scoring > 5 scores at day 7 after cardiac surgery, is associated with an increase in M-MDSCs and elevated levels of the anti-inflammatory cytokine IL-10, related to higher rate of hospital infections, prolonged intensive care unit stay and higher mortality.Aim. To defne the role of myeloid-derived suppressor cells in the development of persistent multiple organ dysfunction followed cardiac surgeries with cardiopulmonary bypass.Methods. 40 patients who have undergone cardiac surgery were included in the study. Granulocyte myeloid-derived suppressor cells (G-MDSC) were defned as cells with the HLA-DR– / CD11Ξ²+ / CD15+ / CD33+ phenotype, and monocytic MDSC (M-MDSC) as cells with the HLA-DR– / CD11Ξ²+ / CD14+ / CD33+ phenotype using flow cytometry. Levels of cytokines, IL-1Ξ², IL-6, TNF-Ξ±, and IL-10 were measured with an enzyme immunoassay. All patients were assigned to three groups: Group 1 – patients with the uncomplicated postoperative period (n = 14), Group 2 – patients with non-persistent MODS and its early resolution (n = 16), and Group 3 – patients with persistent MODS at day 7.Results. We observed an increase in M-MDSCs and G-MDSC at day 1 following cardiac surgery. The most pronounced increase was found in monocytic-myeloid derived suppressor cells, i.e. an 8-fold increase in M-MDSCs in all study groups at day 1 after surgery. The number of M-MDSCs remained high in patients with persistent MODS at day 7 after cardiac surgery. Levels of IL-6 and IL-10 increased at day 1 after surgery. IL-6 reached its peak level, signifcantly exceeding baseline levels. By day 7, blood levels of all cytokines have decreased, except IL-10 levels, which remained above the baseline in patients with persistent MODS.Conclusion. An increase in M-MDSCs and elevated serum levels of the anti-inflammatory cytokine IL-10 have been found in patients regardless of the presence or absence of the complications in the early postoperative period after cardiac surgery with cardiopulmonary bypass. Persistent MODS with the SOFA scoring > 5 scores at day 7 after cardiac surgery, is associated with an increase in M-MDSCs and elevated levels of the anti-inflammatory cytokine IL-10, related to higher rate of hospital infections, prolonged intensive care unit stay and higher mortality

    Π—Π½Π°Ρ‡Π΅Π½ΠΈΠ΅ эритроцитсодСрТащих ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ² донорской ΠΊΡ€ΠΎΠ²ΠΈ Π² объСмС ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎΠ³ΠΎ заполнСния ΠΊΠΎΠ½Ρ‚ΡƒΡ€Π° искусствСнного кровообращСния Π² Ρ€Π°Π·Π²ΠΈΡ‚ΠΈΠΈ систСмного воспалСния ΠΏΡ€ΠΈ ΠΊΠΎΡ€Ρ€Π΅ΠΊΡ†ΠΈΠΈ Π²Ρ€ΠΎΠΆΠ΄Π΅Π½Π½Ρ‹Ρ… ΠΏΠΎΡ€ΠΎΠΊΠΎΠ² сСрдца Ρƒ Π΄Π΅Ρ‚Π΅ΠΉ

    Get PDF
    Various pathological factors accompanying any cardiac surgery can cause intraoperative systemic inflammatory responses (SIR). As the number of cardiac surgical interventions grows worldwide, the issue of SIR prevention appears highly relevant.Aim of the study. To determine the effect of not using donor blood components in the priming of the cardiopulmonary bypass circuit in children with septal congenital heart defects, operated under cardiopulmonary bypass, on the severity of SIR.Material and methods. A prospective, randomized study included 40 children with a median age of 14 [12–22.5] months and weight of 8.8 [7.25–11] kg. All patients underwent radical correction of septal defect under cardiopulmonary bypass. The patients were divided into two groups depending on the use of donor blood components for priming the CPB. The severity of SIR was assessed using four specific serum biomarkers such as interleukin 1b (IL-1b), interleukin 6 (IL-6), interleukin 10 (IL-10), and tumor necrosis factor alpha (TNF-Ξ±), measured before the operation, after the CPB and 16 hours after the surgery. In addition, the intra- and postoperative periods were evaluated.Results. The safety of the proposed strategy of skipping the donor blood was confirmed by lack of any organ dysfunction in all patients, as well as a significant difference in the balance of oxygen delivery and consumption. In addition, the levels of systemic inflammation markers after CPB were significantly higher in patients who had transfusion: IL-1b was 3.3 [3.2–3.48] pg/mL vs 2.86 [2.7–3.11] pg/mL (P=0.003) and TNF-Ξ± reached 1.81 [1.37–3.3] pg/mL vs 1.33 [1.26–1.76] pg/mL (P=0.034). Meanwhile, 16 hours post surgery, IL-6 and IL-10 levels were significantly higher in the group using donor blood components with IL-6 being 48.91 [33.89–57.6] pg/mL vs 31.56 [26.83–48.89] pg/mL (P=0.087) and IL-10 reaching 0.8 [0.76–1.43] pg/mL vs 0.69 [0.6–0.83] pg/mL (P=0.005).Conclusion. The study demonstrates and confirms the safety and efficacy of cardiopulmonary bypass without using donor blood components to reduce the severity of the systemic inflammatory response in children undergoing correction of septal congenital heart defects.Π‘ΠΎΠ»ΡŒΡˆΠΎΠ΅ количСство ΠΏΠ°Ρ‚ΠΎΠ³Π΅Π½Π½Ρ‹Ρ… Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠ², ΡΠΎΠΏΡ€ΠΎΠ²ΠΎΠΆΠ΄Π°ΡŽΡ‰ΠΈΡ… Π»ΡŽΠ±ΡƒΡŽ ΠΊΠ°Ρ€Π΄ΠΈΠΎΡ…ΠΈΡ€ΡƒΡ€Π³ΠΈΡ‡Π΅ΡΠΊΡƒΡŽ ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΡŽ, ΠΏΡ€ΠΈΠ²ΠΎΠ΄ΠΈΡ‚ ΠΊ возникновСнию систСмного Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΎΡ‚Π²Π΅Ρ‚Π° (Π‘Π’Πž) Π² ΠΈΠ½Ρ‚Ρ€Π°ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΎΠ½Π½ΠΎΠΌ ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π΅. Учитывая Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½Ρ‹ΠΉ рост количСства кардиохирургичСских Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π² Π² ΠΌΠΈΡ€Π΅, Π°ΠΊΡ‚ΡƒΠ°Π»ΡŒΠ½ΠΎΠΉ являСтся Π·Π°Π΄Π°Ρ‡Π° ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠΈ Π‘Π’Πž.ЦСль исслСдования: ΡƒΡΡ‚Π°Π½ΠΎΠ²ΠΈΡ‚ΡŒ влияниС ΠΎΡ‚ΠΊΠ°Π·Π° ΠΎΡ‚ примСнСния ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ² донорской ΠΊΡ€ΠΎΠ²ΠΈ Π² объСмС ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎΠ³ΠΎ заполнСния Π°ΠΏΠΏΠ°Ρ€Π°Ρ‚Π° искусствСнного кровообращСния Ρƒ Π΄Π΅Ρ‚Π΅ΠΉ с ΡΠ΅ΠΏΡ‚Π°Π»ΡŒΠ½Ρ‹ΠΌΠΈ Π²Ρ€ΠΎΠΆΠ΄Π΅Π½Π½Ρ‹ΠΌΠΈ ΠΏΠΎΡ€ΠΎΠΊΠ°ΠΌΠΈ сСрдца (Π’ΠŸΠ‘), ΠΎΠΏΠ΅Ρ€ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Ρ… Π² условиях искусствСнного кровообращСния (ИК), Π½Π° Π²Ρ‹Ρ€Π°ΠΆΠ΅Π½Π½ΠΎΡΡ‚ΡŒ Π‘Π’Πž.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ проспСктивноС, Ρ€Π°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠ΅ исслСдованиС Π²ΠΊΠ»ΡŽΡ‡ΠΈΠ»ΠΈ 40 Π΄Π΅Ρ‚Π΅ΠΉ, ΠΌΠ΅Π΄ΠΈΠ°Π½Π½Ρ‹ΠΉ возраст ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… составил 14 [12–22,5] мСсяцСв, вСс β€” 8,8 [7,25–11] ΠΊΠ³. ВсСм ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π°ΠΌ ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Ρ€Π°Π΄ΠΈΠΊΠ°Π»ΡŒΠ½ΡƒΡŽ ΠΊΠΎΡ€Ρ€Π΅ΠΊΡ†ΠΈΡŽ ΡΠ΅ΠΏΡ‚Π°Π»ΡŒΠ½Ρ‹Ρ… Π’ΠŸΠ‘ Π² условиях ИК. ΠŸΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² Ρ€Π°Π·Π΄Π΅Π»ΠΈΠ»ΠΈ Π½Π° 2 Π³Ρ€ΡƒΠΏΠΏΡ‹, Π² зависимости ΠΎΡ‚ использования ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ² донорской ΠΊΡ€ΠΎΠ²ΠΈ Π² объСмС ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎΠ³ΠΎ заполнСния Π°ΠΏΠΏΠ°Ρ€Π°Ρ‚Π° искусствСнного кровообращСния. Π‘Ρ‚Π΅ΠΏΠ΅Π½ΡŒ выраТСнности Π‘Π’Πž ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ с использованиСм Ρ‡Π΅Ρ‚Ρ‹Ρ€Π΅Ρ… спСцифичСских ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ΠΎΠ² Π² сывороткС ΠΊΡ€ΠΎΠ²ΠΈ: ΠΈΠ½Ρ‚Π΅Ρ€Π΅Π»Π΅ΠΉΠΊΠΈΠ½ 1b (IL-1b), ΠΈΠ½Ρ‚Π΅Ρ€Π»Π΅ΠΉΠΊΠΈΠ½ 6 (IL-6), ΠΈΠ½Ρ‚Π΅Ρ€Π»Π΅ΠΉΠΊΠΈΠ½ 10 (IL-10) ΠΈ Ρ„Π°ΠΊΡ‚ΠΎΡ€ Π½Π΅ΠΊΡ€ΠΎΠ·Π° ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ Π°Π»ΡŒΡ„Π° (TNF-Ξ±), ΠΈΠ·ΠΌΠ΅Ρ€Π΅Π½Π½Ρ‹Ρ… Π΄ΠΎ Π½Π°Ρ‡Π°Π»Π° ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΈ, послС Π·Π°Π²Π΅Ρ€ΡˆΠ΅Π½ΠΈΡ ИК ΠΈ Ρ‡Π΅Ρ€Π΅Π· 16 часов послС ΠΎΠΏΠ΅Ρ€Π°Ρ‚ΠΈΠ²Π½ΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π°. ΠšΡ€ΠΎΠΌΠ΅ Ρ‚ΠΎΠ³ΠΎ, ΠΏΡ€ΠΎΠ²Π΅Π»ΠΈ Π°Π½Π°Π»ΠΈΠ· тСчСния ΠΈΠ½Ρ‚Ρ€Π°- ΠΈ послСопСрационного ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π°.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Π‘Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡ‚ΡŒ ΠΏΡ€Π΅Π΄Π»ΠΎΠΆΠ΅Π½Π½ΠΎΠΉ стратСгии ΠΎΡ‚ΠΊΠ°Π·Π° ΠΎΡ‚ использования донорской ΠΊΡ€ΠΎΠ²ΠΈ ΠΏΠΎΠ΄Ρ‚Π²Π΅Ρ€Π΄ΠΈΠ»ΠΈ отсутствиСм ΠΊΠ°ΠΊΠΈΡ…-Π»ΠΈΠ±ΠΎ ΠΎΡ€Π³Π°Π½Π½Ρ‹Ρ… дисфункций Ρƒ всСх ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ², Π° Ρ‚Π°ΠΊΠΆΠ΅ Π·Π½Π°Ρ‡ΠΈΠΌΠΎΠΉ Ρ€Π°Π·Π½ΠΈΡ†Ρ‹ ΠΏΠΎ показатСлям баланса доставки ΠΈ потрСблСния кислорода. Помимо этого, значСния ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ΠΎΠ² Π‘Π’Πž IL-1b (pg/ml) β€” 2,86 [2,7–3,11] vs 3,3 [3,2–3,48] (p=0,003) ΠΈ TNF-Ξ± (pg/ml) β€” 1,33 [1,26–1,76] vs 1,81 [1,37–3,3] (p=0,034) ΠΈΠΌΠ΅Π»ΠΈ Π±ΠΎΠ»Π΅Π΅ высокиС значСния срСди ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с трансфузиСй Π² Ρ‚ΠΎΡ‡ΠΊΠ΅ послС Π·Π°Π²Π΅Ρ€ΡˆΠ΅Π½ΠΈΡ ИК. ΠŸΡ€ΠΈ этом IL-6 (pg/ml) β€” 31,56 [26,83–48,89] vs 48,91 [33,89–57,6] (p=0,087) ΠΈ IL-10 (pg/ml) β€” 0,69 [0,6–0,83] vs 0,8 [0,76–1,43] (p=0,005) Π±Ρ‹Π»ΠΈ статистичСски Π·Π½Π°Ρ‡ΠΈΠΌΠΎ Π²Ρ‹ΡˆΠ΅ Π² Π³Ρ€ΡƒΠΏΠΏΠ΅ с использованиСм ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ² донорской ΠΊΡ€ΠΎΠ²ΠΈ Ρ‡Π΅Ρ€Π΅Π· 16 часов послС ΠΎΠΏΠ΅Ρ€Π°Ρ‚ΠΈΠ²Π½ΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π°.Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Обоснована ΠΈ Π΄ΠΎΠΊΠ°Π·Π°Π½Π° Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡ‚ΡŒ ΠΈ ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ искусствСнного кровообращСния Π±Π΅Π· использования ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ² донорской ΠΊΡ€ΠΎΠ²ΠΈ для сниТСния выраТСнности систСмного Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΎΡ‚Π²Π΅Ρ‚Π° Ρƒ Π΄Π΅Ρ‚Π΅ΠΉ ΠΏΡ€ΠΈ ΠΊΠΎΡ€Ρ€Π΅ΠΊΡ†ΠΈΠΈ ΡΠ΅ΠΏΡ‚Π°Π»ΡŒΠ½Ρ‹Ρ… Π²Ρ€ΠΎΠΆΠ΄Π΅Π½Π½Ρ‹Ρ… ΠΏΠΎΡ€ΠΎΠΊΠΎΠ² сСрдца

    Анализ Π³ΠΎΡΠΏΠΈΡ‚Π°Π»ΡŒΠ½Ρ‹Ρ… ΠΈ ΠΎΡ‚Π΄Π°Π»Π΅Π½Π½Ρ‹Ρ… Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚ΠΎΠ² чрСскоТного ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½ΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π° с ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΊΠΎΠΉ ΡΠΊΡΡ‚Ρ€Π°ΠΊΠΎΡ€ΠΏΠΎΡ€Π°Π»ΡŒΠ½ΠΎΠΉ ΠΌΠ΅ΠΌΠ±Ρ€Π°Π½Π½ΠΎΠΉ оксигСнации Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с ΠΈΡˆΠ΅ΠΌΠΈΡ‡Π΅ΡΠΊΠΎΠΉ болСзнью сСрдца

    Get PDF
    Aim. To analyze in-hospital and long-term (12 months) results of percutaneous coronary intervention (PCI) supported by extracorporeal membrane oxygenation (ECMO) in patients with stable coronary heart disease and multivessel coronary artery disease, and to justify the use of such approach in the treatment of this group of patients.Methods. The retrospective analysis included 13 patients with stable coronary artery and multivessel coronary disease. The mean SYNTAX score before the intervention was 31.4Β±10.8. Between 30 days and 12 months in the postoperative period, the frequency and type of the following major adverse cardiovascular events (MACE) was assessed: all-cause death, myocardial infarction, stroke, repeat revascularization. Twelve months after the event, the data on the frequency and type of adverse cardiovascular events were collected by means of telephone follow-up.Results. Coronary intervention supported by ECMO was performed in all patients. 8 (61.6%) patients required an open surgical approach for ECMO cannula insertion. Door to balloon time was 109.6Β±79.2 minutes. The mean duration of ECMO support was 101.7Β±45.4 minutes. Haemodynamic instability, abnormalities in pulmonary gas exchange and rhythm disturbances were not revealed during primary PCI, making it possible to wean off the ECMO post-PCI. The mean residual SYNTAX score was 9.3Β±11.8. BARC class β‰₯3 bleeding complications were observed in 6 of 13 patients. Long-term major adverse cardiovascular events with fatal outcomes occurred in 3 (23.1%) patients.Conclusion. Supporting high-risk PCI with ECMO in patients with stable coronary artery disease, multivessel coronary artery disease and low left ventricular ejection fraction made it possible to successfully perform the intervention in all patients. Nevertheless, the long-term (12 months) results show a high percentage of recurrent myocardial infarction, which can be associated with high residual SYNTAX score.ЦСль. ΠŸΡ€ΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Ρ‚ΡŒ Π³ΠΎΡΠΏΠΈΡ‚Π°Π»ΡŒΠ½Ρ‹Π΅ ΠΈ ΠΎΡ‚Π΄Π°Π»Π΅Π½Π½Ρ‹Π΅ (12 мСс.) Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ чрСскоТного ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½ΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π° (Π§ΠšΠ’) с ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΡΠΊΡΡ‚Ρ€Π°ΠΊΠΎΡ€ΠΏΠΎΡ€Π°Π»ΡŒΠ½ΠΎΠΉ ΠΌΠ΅ΠΌΠ±Ρ€Π°Π½Π½ΠΎΠΉ оксигСнации (ЭКМО) Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с ΠΈΡˆΠ΅ΠΌΠΈΡ‡Π΅ΡΠΊΠΎΠΉ болСзнью сСрдца (Π˜Π‘Π‘) ΠΈ многососудистым ΠΏΠΎΡ€Π°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½Ρ‹Ρ… Π°Ρ€Ρ‚Π΅Ρ€ΠΈΠΉ (КА) с обоснованиСм примСнСния Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ…ΠΎΠ΄Π° ΠΏΡ€ΠΈ рСваскуляризации ΠΌΠΈΠΎΠΊΠ°Ρ€Π΄Π°.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ рСтроспСктивный Π°Π½Π°Π»ΠΈΠ· Π²ΠΊΠ»ΡŽΡ‡Π΅Π½Ρ‹ 13 Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… ΡΡ‚Π°Π±ΠΈΠ»ΡŒΠ½ΠΎΠΉ Π˜Π‘Π‘ Π² сочСтании с многососудистым ΠΏΠΎΡ€Π°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ КА. Π‘Ρ€Π΅Π΄Π½ΠΈΠΉ Π±Π°Π»Π» ΠΏΠΎ шкалС SYNTAX ΠΏΠ΅Ρ€Π΅Π΄ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΠΎΠΌ составил 31,4Β±10,8. Π’ послСопСрационном ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π΅ ΠΎΡ†Π΅Π½Π΅Π½Π° частота ΠΈ структура ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΊΠΎΠ½Π΅Ρ‡Π½ΠΎΠΉ Ρ‚ΠΎΡ‡ΠΊΠΈ, Π²ΠΊΠ»ΡŽΡ‡Π°ΡŽΡ‰Π΅ΠΉ ΡΠ΅Ρ€ΡŒΠ΅Π·Π½Ρ‹Π΅ нСблагоприятныС кардиоваскулярныС события (MACCE): ΡΠΌΠ΅Ρ€Ρ‚ΡŒ ΠΎΡ‚ всСх ΠΏΡ€ΠΈΡ‡ΠΈΠ½, ΠΈΠ½Ρ„Π°Ρ€ΠΊΡ‚ ΠΌΠΈΠΎΠΊΠ°Ρ€Π΄Π°, ΠΈΠ½ΡΡƒΠ»ΡŒΡ‚, повторная рСваскуляризация ΠΌΠΈΠΎΠΊΠ°Ρ€Π΄Π° Π½Π° протяТСнии 30 Π΄Π½Π΅ΠΉ ΠΈ 12 мСс. Π§Π΅Ρ€Π΅Π· 12 мСс. послС индСксного события с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ Ρ‚Π΅Π»Π΅Ρ„ΠΎΠ½Π½ΠΎΠ³ΠΎ опроса Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½ ΡƒΡ‡Π΅Ρ‚ частоты ΠΈ структуры нСблагоприятных кардиоваскулярных событий.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. ΠšΠΎΡ€ΠΎΠ½Π°Ρ€Π½ΠΎΠ΅ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΠΎ с ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΊΠΎΠΉ ЭКМО ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΎ всСм Π±ΠΎΠ»ΡŒΠ½Ρ‹ΠΌ. Π’ΠΎΡΡŒΠΌΠΈ (61,6%) ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π°ΠΌ установка канюль ЭКМО ΠΏΡ€ΠΎΠΈΠ·Π²Π΅Π΄Π΅Π½Π° хирургичСским способом. Π’ ΠΎΡΡ‚Π°Π»ΡŒΠ½Ρ‹Ρ… случаях канюли устанавливали ΠΏΡƒΠ½ΠΊΡ†ΠΈΠΎΠ½Π½ΠΎ с ΠΏΠΎΡΠ»Π΅Π΄ΡƒΡŽΡ‰ΠΈΠΌ ΡƒΡˆΠΈΠ²Π°Π½ΠΈΠ΅ΠΌ сосудистой стСнки устройством ProStar XL. Π”Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ ΠΏΡ€ΠΎΡ†Π΅Π΄ΡƒΡ€Ρ‹ Π§ΠšΠ’ составила 109,6Β±79,2 ΠΌΠΈΠ½. Π‘Ρ€Π΅Π΄Π½Π΅Π΅ врСмя ΠΏΠΎΠ΄ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΡ Π°ΠΏΠΏΠ°Ρ€Π°Ρ‚Π° ЭКМО – 101,7Β±45,4 ΠΌΠΈΠ½. ΠŸΡ€ΠΈ Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ основного этапа Π§ΠšΠ’ ΡΠ΅Ρ€ΡŒΠ΅Π·Π½Ρ‹Ρ… ΠΎΡ‚ΠΊΠ»ΠΎΠ½Π΅Π½ΠΈΠΉ Π³Π΅ΠΌΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ, Π³Π°Π·ΠΎΠΎΠ±ΠΌΠ΅Π½Π° ΠΈ Π½Π°Ρ€ΡƒΡˆΠ΅Π½ΠΈΠΉ Ρ€ΠΈΡ‚ΠΌΠ° Π½Π΅ выявлСно, Ρ‡Ρ‚ΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΎ ΠΎΡ‚ΠΊΠ»ΡŽΡ‡ΠΈΡ‚ΡŒΡΡ ΠΎΡ‚ циркуляторной ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΊΠΈ Π² Ρ€Π΅Π½Ρ‚Π³Π΅Π½ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΎΠ½Π½ΠΎΠΉ послС Π§ΠšΠ’. Π‘Ρ€Π΅Π΄Π½ΠΈΠΉ остаточный Π±Π°Π»Π» ΠΏΠΎ шкалС SYNTAX составил 9,3Β±11,8. ГСморрагичСскиС ослоТнСния ΠΏΠΎ шкалС BARC β‰₯3 ΠΎΡ‚ΠΌΠ΅Ρ‡Π΅Π½Ρ‹ Ρƒ 6 ΠΈΠ· 13 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ². НСблагоприятныС кардиоваскулярныС события Π² ΠΎΡ‚Π΄Π°Π»Π΅Π½Π½ΠΎΠΌ ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π΅ с Π»Π΅Ρ‚Π°Π»ΡŒΠ½Ρ‹ΠΌ исходом зарСгистрированы Π² 3 (23,1%) случаях.Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. ИспользованиС ЭКМО Π² качСствС ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΊΠΈ кровообращСния ΠΏΡ€ΠΈ Π§ΠšΠ’ высокого риска Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² со ΡΡ‚Π°Π±ΠΈΠ»ΡŒΠ½ΠΎΠΉ Π˜Π‘Π‘ Π² сочСтании с многососудистым ΠΏΠΎΡ€Π°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ КА ΠΈ Π½ΠΈΠ·ΠΊΠΎΠΉ Ρ„Ρ€Π°ΠΊΡ†ΠΈΠ΅ΠΉ выброса Π»Π΅Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡ΠΊΠ° ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΎ Π²Ρ‹ΠΏΠΎΠ»Π½ΠΈΡ‚ΡŒ ΡƒΡΠΏΠ΅ΡˆΠ½ΠΎΠ΅ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΠΎ всСм участникам исслСдования. Π’Π΅ΠΌ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅ ΠΎΡ‚Π΄Π°Π»Π΅Π½Π½Ρ‹Π΅ (12 мСс.) Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ ΠΏΠΎΠΊΠ°Π·Ρ‹Π²Π°ΡŽΡ‚ Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΉ ΠΏΡ€ΠΎΡ†Π΅Π½Ρ‚ ΠΏΠΎΠ²Ρ‚ΠΎΡ€Π½ΠΎΠ³ΠΎ ΠΈΠ½Ρ„Π°Ρ€ΠΊΡ‚Π° ΠΌΠΈΠΎΠΊΠ°Ρ€Π΄Π°, Ρ‡Ρ‚ΠΎ, Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎ, связано с высоким остаточным Π±Π°Π»Π»ΠΎΠΌ ΠΏΠΎ шкалС Syntax

    ΠœΠ΅Ρ…Π°Π½ΠΈΡ‡Π΅ΡΠΊΠ°Ρ ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΊΠ° кровообращСния ΠΏΡ€ΠΈ чрСскоТном ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½ΠΎΠΌ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π΅ высокого риска

    Get PDF
    High-risk percutaneous coronary intervention involves technical challenges in performing revascularization, hemodynamic instability and heart rate variability, and possible complications. Mechanical circulatory support devices ensure hemodynamic stability and expansion of opportunities for revascularization. Current methods include the following devices: intra-aortic balloon counterpulsation, Impella, TandemHeart, and venoarterial extracorporeal membrane oxygenation. The review accumulates current evidences on the use of these devices for mechanical circulatory support during high-risk percutaneous coronary intervention from the reports, registries, randomized and observational studies, as well as clinical trials.ЧрСскоТноС ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½ΠΎΠ΅ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΠΎ высокого риска ΠΏΠΎΠ΄Ρ€Π°Π·ΡƒΠΌΠ΅Π²Π°Π΅Ρ‚ тСхничСскиС трудности ΠΏΡ€ΠΈ Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ рСваскуляризации, Π½Π΅ΡΡ‚Π°Π±ΠΈΠ»ΡŒΠ½ΠΎΡΡ‚ΡŒ сСрдСчного Ρ€ΠΈΡ‚ΠΌΠ° ΠΈ Π³Π΅ΠΌΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ ΠΈ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½Ρ‹Π΅ ослоТнСния. Одним ΠΈΠ· способов обСспСчСния гСмодинамичСской ΡΡ‚Π°Π±ΠΈΠ»ΡŒΠ½ΠΎΡΡ‚ΠΈ ΠΈ Ρ€Π°ΡΡˆΠΈΡ€Π΅Π½ΠΈΡ возмоТностСй для рСваскуляризации ΡΠ²Π»ΡΡŽΡ‚ΡΡ использованиС устройств мСханичСской ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΊΠΈ кровообращСния. На Π΄Π°Π½Π½Ρ‹ΠΉ ΠΌΠΎΠΌΠ΅Π½Ρ‚ арсСнал ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠ² прСдставлСн ΡΠ»Π΅Π΄ΡƒΡŽΡ‰ΠΈΠΌΠΈ устройствами: Π²Π½ΡƒΡ‚Ρ€ΠΈΠ°ΠΎΡ€Ρ‚Π°Π»ΡŒΠ½Π°Ρ баллонная ΠΊΠΎΠ½Ρ‚Ρ€ΠΏΡƒΠ»ΡŒΡΠ°Ρ†ΠΈΡ, Impella, TandemHeart ΠΈ Π²Π΅Π½ΠΎ-Π°Ρ€Ρ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½Π°Ρ мСмбранная оксигСнация. Π’ ΠΎΠ±Π·ΠΎΡ€Π΅ рассмотрСны Π°ΠΊΡ‚ΡƒΠ°Π»ΡŒΠ½Ρ‹Π΅ сообщСния, Π΄Π°Π½Π½Ρ‹Π΅ рСгистров, Ρ€Π°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Ρ… ΠΈ Π½Π°Π±Π»ΡŽΠ΄Π°Ρ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… исслСдований, Π° Ρ‚Π°ΠΊΠΆΠ΅ клиничСскиС ΠΏΡ€ΠΎΡ‚ΠΎΠΊΠΎΠ»Ρ‹, посвящСнныС использованию этих устройств для мСханичСской ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΊΠΈ кровообращСния Π²ΠΎ врСмя чрСскоТного ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½ΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π° высокого риска

    ΠžΡ€Π³Π°Π½ΠΎΠΏΡ€ΠΎΡ‚Π΅ΠΊΡ‚ΠΈΠ²Π½Ρ‹Π΅ эффСкты ΡΠΊΡΡ‚Ρ€Π°ΠΊΠΎΡ€ΠΏΠΎΡ€Π°Π»ΡŒΠ½ΠΎΠΉ ΠΌΠ΅ΠΌΠ±Ρ€Π°Π½Π½ΠΎΠΉ оксигСнации ΠΈ Π²Π½ΡƒΡ‚Ρ€ΠΈΠ°ΠΎΡ€Ρ‚Π°Π»ΡŒΠ½ΠΎΠΉ Π±Π°Π»Π»ΠΎΠ½Π½ΠΎΠΉ ΠΊΠΎΠ½Ρ‚Ρ€ΠΏΡƒΠ»ΡŒΡΠ°Ρ†ΠΈΠΈ ΠΏΡ€ΠΈ чрСскоТном ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½ΠΎΠΌ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π΅ высокого риска Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с острым ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½Ρ‹ΠΌ синдромом

    Get PDF
    Purpose of the study: to evaluate the organoprotective effects of veno-arterial extracorporeal membrane oxygenation and intra-aortic balloon pump during high-risk percutaneous coronary intervention in acute coronary syndrome.Materials and methods. Patients required mechanical circulatory support (n=51) were divided into two study groups: patients who received mechanical circulatory support by veno-arterial extracorporeal membrane oxygenation (ECMO) (Group 1, n=29) during high-risk percutaneous coronary intervention, and Group 2 patients who received mechanical circulatory support by intra-aortic balloon pump (IABP) during high-risk percutaneous coronary intervention (Group 2, n=22). The dynamics of instrumental parameters and laboratory markers of organ damage were evaluated by electrocardiography, echocardiography, determining troponin I, creatine phosphokinases and creatinine levels, NGAL, venous blood saturation to compare the organoprotective properties of mechanical circulation support in the intra- and postoperative period.Results. The following values of the parameters were found the next day after the intervention: troponin I β€” 0.18 (0.1; 2.3) ng/ml in the ECMO group and 1.64 (0.92; 2.36) ng/ml in the IABP group (P=0.045); serum NGAL β€”139.4 (88.1; 166.7) ng/ml in the ECMO group and 212.3 (102; 279) in the IABP group (P=0.027); renal dysfunction (stages R, I, F according to RIFLE) β€” 2 (6.8%) observations in the ECMO group and 7 (31.8%) in the IABP group (P=0.021); multiple organ failure (2 or more points according to SOFA) β€” 3 (10.3%) cases in the ECMO group and 12 (54.5%) in the IABP group (P=0.001).Conclusion. Veno-arterial ECMO in comparison with IABP has a more pronounced organoprotective effect by achieving better hemodynamic stability, which, in turn, prevents hypoxia and the subsequent development of organ dysfunction. In addition, in conditions of veno-arterial ECMO, better completeness and quality of revascularization is ensured, and hospital mortality is also reduced.ЦСль исслСдования: ΠΎΡ†Π΅Π½ΠΈΡ‚ΡŒ ΠΎΡ€Π³Π°Π½ΠΎΠΏΡ€ΠΎΡ‚Π΅ΠΊΡ‚ΠΈΠ²Π½Ρ‹Π΅ эффСкты Π²Π΅Π½ΠΎ-Π°Ρ€Ρ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΡΠΊΡΡ‚Ρ€Π°ΠΊΠΎΡ€ΠΏΠΎΡ€Π°Π»ΡŒΠ½ΠΎΠΉ ΠΌΠ΅ΠΌΠ±Ρ€Π°Π½Π½ΠΎΠΉ оксигСнации (ЭКМО) ΠΈ Π²Π½ΡƒΡ‚Ρ€ΠΈΠ°ΠΎΡ€Ρ‚Π°Π»ΡŒΠ½ΠΎΠΉ Π±Π°Π»Π»ΠΎΠ½Π½ΠΎΠΉ ΠΊΠΎΠ½Ρ‚Ρ€ΠΏΡƒΠ»ΡŒΡΠ°Ρ†ΠΈΠΈ (Π’ΠΠ‘Πš) Π²ΠΎ врСмя чрСскоТного ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½ΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π° высокого риска (Π§ΠšΠ’ Π’Π ) ΠΏΡ€ΠΈ остром ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½ΠΎΠΌ синдромС.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ исслСдованиС Π²ΠΊΠ»ΡŽΡ‡ΠΈΠ»ΠΈ 51 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π° ΠΈ Ρ€Π°Π·Π΄Π΅Π»ΠΈΠ»ΠΈ Π½Π° Π΄Π²Π΅ исслСдуСмыС Π³Ρ€ΡƒΠΏΠΏΡ‹. Π“Ρ€ΡƒΠΏΠΏΠ° 1 (Π§ΠšΠ’+ЭКМО) n=29 β€” ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΌ Π²ΠΎ врСмя чрСскоТного ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½ΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π° высокого риска ΠΎΠΊΠ°Π·Ρ‹Π²Π°Π»Π°ΡΡŒ мСханичСская ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΊΠ° кровообращСния Π² Π²ΠΈΠ΄Π΅ Π²Π΅Π½ΠΎ-Π°Ρ€Ρ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΡΠΊΡΡ‚Ρ€Π°ΠΊΠΎΡ€ΠΏΠΎΡ€Π°Π»ΡŒΠ½ΠΎΠΉ ΠΌΠ΅ΠΌΠ±Ρ€Π°Π½Π½ΠΎΠΉ оксигСнации. Π“Ρ€ΡƒΠΏΠΏΠ° 2 (Π§ΠšΠ’+Π’ΠΠ‘Πš) n=22 β€” ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΌ Π²ΠΎ врСмя чрСскоТного ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½ΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π° высокого риска ΠΎΠΊΠ°Π·Ρ‹Π²Π°Π»Π°ΡΡŒ мСханичСская ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΊΠ° кровообращСния Π² Π²ΠΈΠ΄Π΅ Π²Π½ΡƒΡ‚Ρ€ΠΈΠ°ΠΎΡ€Ρ‚Π°Π»ΡŒΠ½ΠΎΠΉ Π±Π°Π»Π»ΠΎΠ½Π½ΠΎΠΉ ΠΊΠΎΠ½Ρ‚Ρ€ΠΏΡƒΠ»ΡŒΡΠ°Ρ†ΠΈΠΈ. Для сравнСния ΠΎΡ€Π³Π°Π½ΠΎΠΏΡ€ΠΎΡ‚Π΅ΠΊΡ‚ΠΈΠ²Π½Ρ‹Ρ… свойств мСханичСской ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΊΠΈ кровообращСния Π² ΠΈΠ½Ρ‚Ρ€Π°β€” ΠΈ послСопСрационном ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π΅ ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡƒ ΠΈΠ½ΡΡ‚Ρ€ΡƒΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½Ρ‹Ρ… ΠΈ Π»Π°Π±ΠΎΡ€Π°Ρ‚ΠΎΡ€Π½Ρ‹Ρ… ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ΠΎΠ² ΠΎΡ€Π³Π°Π½Π½ΠΎΠ³ΠΎ поврСТдСния: элСктрокардиограммы, эхокардиограммы, содСрТания Ρ‚Ρ€ΠΎΠΏΠΎΠ½ΠΈΠ½Π° I, ΠΎΠ±Ρ‰Π΅ΠΉ ΠΈ ΠœΠ’ Ρ„Ρ€Π°ΠΊΡ†ΠΈΠΈ крСатинфосфокиназы, ΠΊΡ€Π΅Π°Ρ‚ΠΈΠ½ΠΈΠ½Π°, NGAL, сатурации Π²Π΅Π½ΠΎΠ·Π½ΠΎΠΉ ΠΊΡ€ΠΎΠ²ΠΈ.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. На ΡΠ»Π΅Π΄ΡƒΡŽΡ‰ΠΈΠ΅ сутки послС Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π° ΠΎΡ‚ΠΌΠ΅Ρ‡Π°Π»ΠΈ ΡΠ»Π΅Π΄ΡƒΡŽΡ‰ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΠΈ исслСдуСмых ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€ΠΎΠ²: Ρ‚Ρ€ΠΎΠΏΠΎΠ½ΠΈΠ½ I β€” 0,18 (0,1; 2,3) Π½Π³/ΠΌΠ» Π² Π³Ρ€ΡƒΠΏΠΏΠ΅ Π§ΠšΠ’+ЭКМО ΠΈ 1,64 (0,92; 2,36) Π½Π³/ΠΌΠ» Π² Π³Ρ€ΡƒΠΏΠΏΠ΅ Π§ΠšΠ’+Π’ΠΠ‘Πš (p=0,045); сывороточный NGAL β€” 139,4 (88,1; 166,7) Π½Π³/ΠΌΠ» Π² Π³Ρ€ΡƒΠΏΠΏΠ΅ Π§ΠšΠ’+ЭКМО ΠΈ 212,3 (102; 279) Π² Π³Ρ€ΡƒΠΏΠΏΠ΅ Π§ΠšΠ’+Π’ΠΠ‘Πš (p=0,027); почСчная дисфункция (стадии R, I, F ΠΏΠΎ RIFLE) β€” 2 (6,8%) наблюдСния Π² Π³Ρ€ΡƒΠΏΠΏΠ΅ Π§ΠšΠ’+ЭКМО ΠΈ 7 (31,8%) Π² Π³Ρ€ΡƒΠΏΠΏΠ΅ Π§ΠšΠ’+Π’ΠΠ‘Πš (p=0,021); полиорганная Π½Π΅Π΄ΠΎΡΡ‚Π°Ρ‚ΠΎΡ‡Π½ΠΎΡΡ‚ΡŒ (2 ΠΈ Π±ΠΎΠ»Π΅Π΅ Π±Π°Π»Π»ΠΎΠ² ΠΏΠΎ SOFA) β€” 3 (10,3%) наблюдСния Π² Π³Ρ€ΡƒΠΏΠΏΠ΅ Π§ΠšΠ’+ЭКМО ΠΈ 12 (54,5%) Π² Π³Ρ€ΡƒΠΏΠΏΠ΅ Π§ΠšΠ’+Π’ΠΠ‘Πš (p=0,001).Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Π’Π΅Π½ΠΎ-Π°Ρ€Ρ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½Π°Ρ ЭКМО ΠΏΠΎ ΡΡ€Π°Π²Π½Π΅Π½ΠΈΡŽ с Π’ΠΠ‘Πš ΠΎΠΊΠ°Π·Ρ‹Π²Π°Π΅Ρ‚ Π±ΠΎΠ»Π΅Π΅ Π²Ρ‹Ρ€Π°ΠΆΠ΅Π½Π½Ρ‹ΠΉ ΠΎΡ€Π³Π°Π½ΠΎΠΏΡ€ΠΎΡ‚Π΅ΠΊΡ‚ΠΈΠ²Π½Ρ‹ΠΉ эффСкт ΠΏΡƒΡ‚Π΅ΠΌ достиТСния гСмодинамичСской ΡΡ‚Π°Π±ΠΈΠ»ΡŒΠ½ΠΎΡΡ‚ΠΈ, Ρ‡Ρ‚ΠΎ, Π² свою ΠΎΡ‡Π΅Ρ€Π΅Π΄ΡŒ, ΠΏΡ€Π΅Π΄ΡƒΠΏΡ€Π΅ΠΆΠ΄Π°Π΅Ρ‚ Ρ€Π°Π·Π²ΠΈΡ‚ΠΈΠ΅ гипоксии ΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΡƒΡŽΡ‰Π΅ΠΉ ΠΎΡ€Π³Π°Π½Π½ΠΎΠΉ дисфункции. ΠšΡ€ΠΎΠΌΠ΅ Ρ‚ΠΎΠ³ΠΎ, Π² условиях Π²Π΅Π½ΠΎ-Π°Ρ€Ρ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ЭКМО обСспСчиваСтся Π»ΡƒΡ‡ΡˆΠ΅Π΅ качСство ΠΈ ΠΏΠΎΠ»Π½ΠΎΡ‚Π° рСваскуляризации, Π° Ρ‚Π°ΠΊΠΆΠ΅ сниТаСтся Π³ΠΎΡΠΏΠΈΡ‚Π°Π»ΡŒΠ½Π°Ρ Π»Π΅Ρ‚Π°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ

    ΠžΠ‘ΠžΠ‘Π•ΠΠΠžΠ‘Π’Π˜ Π”Π˜ΠΠ“ΠΠžΠ‘Π’Π˜ΠšΠ˜ И Π›Π•Π§Π•ΠΠ˜Π― Π’Π―Π–Π•Π›ΠžΠ™ ΠΠžΠ Π’ΠΠ›Π¬ΠΠžΠ™ ΠΠ•Π”ΠžΠ‘Π’ΠΠ’ΠžΠ§ΠΠžΠ‘Π’Π˜ Π£ ΠŸΠžΠ”Π ΠžΠ‘Π’ΠšΠ 14 Π›Π•Π’ НА Π€ΠžΠΠ• Π”Π˜Π‘ΠŸΠ›ΠΠ—Π˜Π˜ Π‘ΠžΠ•Π”Π˜ΠΠ˜Π’Π•Π›Π¬ΠΠžΠ™ ВКАНИ (ΠšΠ›Π˜ΠΠ˜Π§Π•Π‘ΠšΠ˜Π™ БЛУЧАЙ)

    Get PDF
    Medical records of a patient presented with severe aortic and mitral regurgitation and connective tissue dysplasia were reviewed. Clinical, laboratory and instrumental findings were collected at baseline and after the surgery. Long-term outcomes, including quality of life, were estimated.ΠŸΡ€ΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· мСдицинской Π΄ΠΎΠΊΡƒΠΌΠ΅Π½Ρ‚Π°Ρ†ΠΈΠΈ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π° дСтского возраста с Π²Ρ‹Ρ€Π°ΠΆΠ΅Π½Π½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡ‚Π°Ρ‚ΠΎΡ‡Π½ΠΎΡΡ‚ΡŒΡŽ Π°ΠΎΡ€Ρ‚Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΈ ΠΌΠΈΡ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΊΠ»Π°ΠΏΠ°Π½ΠΎΠ² Π½Π° Ρ„ΠΎΠ½Π΅ синдрома Π½Π΅Π΄ΠΈΡ„Ρ„Π΅Ρ€Π΅Π½Ρ†ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠΉ дисплазии ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΉ Ρ‚ΠΊΠ°Π½ΠΈ. Π˜Π·ΡƒΡ‡Π°Π»Π°ΡΡŒ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° клиничСских, Π»Π°Π±ΠΎΡ€Π°Ρ‚ΠΎΡ€Π½Ρ‹Ρ… ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»Π΅ΠΉ, Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚ΠΎΠ² ΠΈΠ½ΡΡ‚Ρ€ΡƒΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½Ρ‹Ρ… исслСдований Π΄ΠΎ ΠΈ послС ΠΎΠΏΠ΅Ρ€Π°Ρ‚ΠΈΠ²Π½ΠΎΠ³ΠΎ лСчСния, Π° Ρ‚Π°ΠΊΠΆΠ΅ ΠΎΡ‚Π΄Π°Π»Π΅Π½Π½Ρ‹Π΅ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹, Π²ΠΊΠ»ΡŽΡ‡Π°Ρ ΠΎΡ†Π΅Π½ΠΊΡƒ качСства ΠΆΠΈΠ·Π½ΠΈ

    ΠšΠ°Ρ€Π΄ΠΈΠΎΠ³Π΅Π½Π½Ρ‹ΠΉ шок: ΠΎΠ±Π½ΠΎΠ²Π»Π΅Π½ΠΈΠ΅

    Get PDF
    Cardiogenic shock is a critical condition characterized by rapid development of multiple organ dysfunction in the absence of intensive care. The article describes AbstractΒ Β Β  modern concepts about pathophysiology and approaches to treat intensive care. The concept of phased therapy as well as methods of mechanical circulatory support are discussed. The working algorithm for choosing the optimal method was proposed.ΠšΠ°Ρ€Π΄ΠΈΠΎΠ³Π΅Π½Π½Ρ‹ΠΉ шок - критичСскоС состояниС, Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ·ΡƒΡŽΡ‰Π΅Π΅ΡΡ молниСносным Ρ€Π°Π·Π²ΠΈΡ‚ΠΈΠ΅ΠΌ ΠΏΠΎΠ»ΠΈΠΎΡ€Π³Π°Π½Π½ΠΎΠΉ нСдостаточности Π² условиях отсутствия интСнсивной Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ. Π’ ΡΡ‚Π°Ρ‚ΡŒΠ΅ описаны соврСмСнныС прСдставлСния ΠΎ направлСниях ΠΏΠ°Ρ‚ΠΎΡ„ΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ, соврСмСнныС ΠΏΠΎΠ΄Ρ…ΠΎΠ΄Ρ‹ ΠΊ интСнсивной Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ, рассматриваСтся концСпция «фазности» Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ, Π° Ρ‚Π°ΠΊΠΆΠ΅ Ρ€Π°ΡΡΠΌΠ°Ρ‚Ρ€ΠΈΠ²Π°ΡŽΡ‚ΡΡ способы мСханичСской ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΊΠΈ кровообращСния ΠΈ прСдлагаСтся Ρ€Π°Π±ΠΎΡ‡ΠΈΠΉ Π°Π»Π³ΠΎΡ€ΠΈΡ‚ΠΌ Π²Ρ‹Π±ΠΎΡ€Π° ΠΎΠΏΡ‚ΠΈΠΌΠ°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΌΠ΅Ρ‚ΠΎΠ΄Π°

    Π­ΠΊΡΡ‚Ρ€Π°ΠΊΠΎΡ€ΠΏΠΎΡ€Π°Π»ΡŒΠ½Π°Ρ мСмбранная оксигСнация ΠΈ соврСмСнныС ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹ дСтоксикации Π² Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ Π²ΠΈΡ€ΡƒΡΠ½ΠΎΠ±Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΈ, обусловлСнной вирусом Π³Ρ€ΠΈΠΏΠΏΠ° A(H1N1) Ρƒ Ρ€ΠΎΠ΄ΠΈΠ»ΡŒΠ½ΠΈΡ†Ρ‹

    Get PDF
    Outbreaks of viral infections have become a global healthcare challenge over the last decade. The 2009β€”2010 flu A (H1N1) outbreak resulted in global pandemia, associated with high morbidity and mortality reaching 31%. Another flu A (H1N1) outbreak occurred in 2015β€”2016. There is a strong probability that it may be repeated in the future. This infection is associated with its high incidence among pregnant women. There are some published reports describing the efficacy and safety of veno%venous extracorporeal membrane oxygenation (ECMO) in patients with severe acute respiratory distress syndrome that is refractory to standard therapeutic options. The article presents a clinical case of a successful use of extracorporeal membrane oxygenation and intermittent renal replacement therapy in a puerpera with acute respiratory distress syndrome caused by flu A (H1N1)-related severe viral and bacterial pneumonia. The positive effects of the combination of veno%venous extracorporeal membrane oxygenation and modern detoxification techniques have been demonstrated. Revealed organizational problemswere related to selection criteria for prescription of extracorporeal gas exchange, as well as to carrying out the procedure in an institution in the deficiency of the experienced staff and corresponding equipment.Π’ΡΠΏΡ‹ΡˆΠΊΠΈ вирусных ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΉ Π² послСднСС дСсятилСтиС стали ΡΠ΅Ρ€ΡŒΠ΅Π·Π½ΠΎΠΉ ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠΎΠΉ для ΠΌΠΈΡ€ΠΎΠ²ΠΎΠ³ΠΎ здравоохранСния. МолниСносноС распространСниС Π³Ρ€ΠΈΠΏΠΏΠ° А (H1N1) Π² 2009β€”2010 Π³Π³. , Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ·ΡƒΡŽΡ‰Π΅Π΅ΡΡ высокой Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡ‚ΡŒΡŽ ΠΈ ΡΠΌΠ΅Ρ€Ρ‚Π½ΠΎΡΡ‚ΡŒΡŽ, Π΄ΠΎΡΡ‚ΠΈΠ³Π°ΡŽΡ‰Π΅ΠΉ 31%, ΠΏΡ€ΠΈΠ²Π΅Π»ΠΎ ΠΏΠΎ сути ΠΊ ΠΏΠ°Π½Π΄Π΅ΠΌΠΈΠΈ, Π·Π°Ρ‚Ρ€ΠΎΠ½ΡƒΠ²ΡˆΠ΅ΠΉ вСсь Π·Π΅ΠΌΠ½ΠΎΠΉ ΡˆΠ°Ρ€. ΠŸΠΎΠ²Ρ‚ΠΎΡ€Π½Π°Ρ пандСмия Π³Ρ€ΠΈΠΏΠΏΠ° A (H1N1) наблюдалась Π² 2015β€”2016 Π³Π³. ΠΈ с высокой Π΄ΠΎΠ»Π΅ΠΉ вСроятности ΠΌΠΎΠΆΠ΅Ρ‚ ΠΏΠΎΠ²Ρ‚ΠΎΡ€ΠΈΡ‚ΡŒΡΡ Π² Π±ΡƒΠ΄ΡƒΡ‰Π΅ΠΌ. ΠžΡΠΎΠ±Π΅Π½Π½ΠΎΡΡ‚ΡŒΡŽ Π΄Π°Π½Π½ΠΎΠΉ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ являСтся высокая частота заболСваСмости срСди Π±Π΅Ρ€Π΅ΠΌΠ΅Π½Π½Ρ‹Ρ… ΠΆΠ΅Π½Ρ‰ΠΈΠ½. Π’ Π»ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Π΅ ΠΈΠΌΠ΅ΡŽΡ‚ΡΡ сообщСния ΠΎ достаточной эффСктивности ΠΈ бСзопасности примСнСния Π²Π΅Π½ΠΎ%Π²Π΅Π½ΠΎΠ·Π½ΠΎΠΉ ΡΠΊΡΡ‚Ρ€Π°ΠΊΠΎΡ€ΠΏΠΎΡ€Π°Π»ΡŒΠ½ΠΎΠΉ ΠΌΠ΅ΠΌΠ±Ρ€Π°Π½Π½ΠΎΠΉ оксигСнации Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с тя%ΠΆΠ΅Π»Ρ‹ΠΌ острым рСспираторным дистрСсс-синдромом, Ρ€Π΅Ρ„Ρ€Π°ΠΊΡ‚Π΅Ρ€Π½ΠΎΠΌ ΠΊ стандартным тСрапСвтичСским мСроприятиям. Π’ ΡΡ‚Π°Ρ‚ΡŒΠ΅ дСмонстрируСтся клиничСский случай ΡƒΡΠΏΠ΅ΡˆΠ½ΠΎΠ³ΠΎ примСнСния ΡΠΊΡΡ‚Ρ€Π°ΠΊΠΎΡ€ΠΏΠΎΡ€Π°Π»ΡŒΠ½ΠΎΠΉ ΠΌΠ΅ΠΌΠ±Ρ€Π°Π½Π½ΠΎΠΉ оксигСнации Π² сочСтании с ΠΌΠ΅Ρ‚ΠΎΠ΄Π°ΠΌΠΈ ΠΈΠ½Ρ‚Π΅Ρ€ΠΌΠΈΡ‚Ρ‚ΠΈΡ€ΡƒΡŽΡ‰Π΅ΠΉ Π·Π°ΠΌΠ΅ΡΡ‚ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΏΠΎΡ‡Π΅Ρ‡Π½ΠΎΠΉ Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Ρƒ Ρ€ΠΎΠ΄ΠΈΠ»ΡŒΠ½ΠΈΡ†Ρ‹ с острым рСспираторным дистрСсс-синдромом, обусловлСнном тяТСлой  вирусно-Π±Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠ΅ΠΉ Π½Π° Ρ„ΠΎΠ½Π΅ Π³Ρ€ΠΈΠΏΠΏΠ° А (H1N1). Π”ΠΎΠΊΠ°Π·Π°Π½Ρ‹ ΠΏΠΎΠ»ΠΎΠΆΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Π΅ эффСкты сочСтанного примСнСния Π²Π΅Π½ΠΎΠ²Π΅Π½ΠΎΠ·Π½ΠΎΠΉ ΡΠΊΡΡ‚Ρ€Π°ΠΊΠΎΡ€ΠΏΠΎΡ€Π°Π»ΡŒΠ½ΠΎΠΉ ΠΌΠ΅ΠΌΠ±Ρ€Π°Π½Π½ΠΎΠΉ оксигСнации ΠΈ соврСмСнных ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠ² дСтоксикации. ΠžΠ±ΠΎΠ·Π½Π°Ρ‡Π΅Π½Ρ‹ ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΡ‹ ΠΎΡ€Π³Π°Π½ΠΈΠ·Π°Ρ†ΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€Π°, возникшиС ΠΊΠ°ΠΊ ΠΏΡ€ΠΈ ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ΠΈΠΈ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΠΉ ΠΊ ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡŽ ΡΠΊΡΡ‚Ρ€Π°ΠΊΠΎΡ€ΠΏΠΎΡ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ Π³Π°Π·ΠΎΠΎΠ±ΠΌΠ΅Π½Π°, Ρ‚Π°ΠΊ ΠΈ связанныС с Π΅Π³ΠΎ Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½ΠΈΠ΅ΠΌ Π² ΡƒΡ‡Ρ€Π΅ΠΆΠ΄Π΅Π½ΠΈΠΈ, Π½Π΅ ΠΈΠΌΠ΅ΡŽΡ‰Π΅ΠΌ ΠΎΠΏΡ‹Ρ‚Π° ΠΈ ΡΠΎΠΎΡ‚Π²Π΅Ρ‚ΡΡ‚Π²ΡƒΡŽΡ‰Π΅Π³ΠΎ тСхничСского оснащСния
    corecore